PT Kalbe Farma (KLBF) Fundamentals 2026 — P/E 9.2x, Revenue Analysis | SniperIQ
PT Kalbe Farma (KLBF) is a ID-listed Healthcare company in Drug Manufacturers - General with a market capitalization of Rp33.03T, trading at Rp730.00 on the JKT. This SniperIQ fundamentals page covers PT Kalbe Farma's valuation (P/E 9.2x, P/B 1.4x), profitability (net margin 10.0%), revenue (Rp35.32T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Kalbe Farma's market cap?
PT Kalbe Farma (KLBF) has a market capitalization of approximately Rp33.03T, trading at Rp730.00 on the JKT. Market cap moves with the live share price.
What is PT Kalbe Farma's P/E ratio?
PT Kalbe Farma's trailing twelve-month P/E ratio is 9.2x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Kalbe Farma?
PT Kalbe Farma runs a net profit margin of 10.0%, a gross margin of 38.7%, and an operating margin of 12.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Kalbe Farma generate?
PT Kalbe Farma reported revenue of Rp35.32T for fiscal year 2025, with net income of Rp3.66T and earnings per share (EPS) of 80.51. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Kalbe Farma pay a dividend?
PT Kalbe Farma offers a trailing dividend yield of about 2.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PT Kalbe Farma financially healthy?
PT Kalbe Farma carries a debt-to-equity ratio of 0.01x and a current ratio of 3.56x, with a market beta of -0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Kalbe Farma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Kalbe Farma (KLBF) the key facts are: market cap Rp33.03T, P/E 9.2x, revenue Rp35.32T, 52-week range 630-1510. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Kalbe Farma's full fundamentals live
Get PT Kalbe Farma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.